Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromperidol maintenance in schizophrenia

J P McEvoy, W H Wilson, T A Ban

    Pharmacopsychiatria
    |May 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Childhood Trauma in People with Psychosis: Implications for Emotion Awareness and Regulation.

    Psychosis·2025
    Same author

    Inflammation and altered metabolism impede efficacy of functional electrical stimulation in critically ill patients.

    Critical care (London, England)·2023
    Same author

    Associations between nutritional energy delivery, bioimpedance spectroscopy and functional outcomes in survivors of critical illness.

    Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2019
    Same author

    Clinical application of the Melbourne risk prediction tool in a high-risk upper abdominal surgical population: an observational cohort study.

    Physiotherapy·2013
    Same author

    Association of postoperative pulmonary complications with delayed mobilisation following major abdominal surgery: an observational cohort study.

    Physiotherapy·2012
    Same author

    Persistent infection with neurotropic herpes viruses and cognitive impairment.

    Psychological medicine·2012
    Same journal

    Prediction of response to stabilizing lithium treatment.

    Pharmacopsychiatria·1983
    Same journal

    Prediction of clinical course by dexamethasone suppression test (DST) response in depressed patients - physiological and clinical construct validity of the DST.

    Pharmacopsychiatria·1983
    Same journal

    Clinical and biological parameters as predictors for antidepressant drug responses in depressed patients.

    Pharmacopsychiatria·1983
    Same journal

    Prediction of course and therapeutic response in psychiatric diseases.

    Pharmacopsychiatria·1983
    Same journal

    Prediction of "natural" course, relapse and prophylactic response in schizophrenic patients.

    Pharmacopsychiatria·1983
    Same journal

    The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.

    Pharmacopsychiatria·1983
    See all related articles

    Bromperidol demonstrated sustained efficacy in patients with psychosis over an extended treatment period. Most patients maintained or improved their condition, with minimal treatment discontinuations due to side effects.

    Area of Science:

    • Psychiatry
    • Clinical Pharmacology

    Background:

    • Antipsychotic medications are crucial for managing psychotic disorders.
    • Haloperidol is a well-established antipsychotic, serving as a benchmark for new treatments.

    Purpose of the Study:

    • To evaluate the long-term efficacy and tolerability of bromperidol.
    • To assess bromperidol's effectiveness in patients who initially responded to it.

    Main Methods:

    • A continuation study involving 23 patients who completed a 4-week trial of bromperidol versus haloperidol.
    • Patients received bromperidol for an additional 8 weeks.

    Main Results:

    • Over 87% of patients maintained or showed further improvement in their condition.
    • Extrapyramidal signs were observed frequently but led to treatment discontinuation in only two patients.

    Related Experiment Videos

    Conclusions:

    • Bromperidol offers sustained therapeutic benefits for patients with psychosis.
    • The drug is generally well-tolerated, with a low rate of discontinuation due to adverse events.